EGFR

This study tests a new daily pill, firmonertinib, against standard chemotherapy for people with advanced non-small cell lung cancer that has certain EGFR mutations (PACC or L861Q). About 300 participants who have not had prior treatment will be randomly assigned to receive either…

This early-stage study tests a new drug called VIR-5525, alone or with another cancer drug (pembrolizumab), in people with advanced solid tumors that have a protein called EGFR. The main goals are to check safety and find the right dose. About 450 adults with tumors that cannot b…

This early-phase study tests a new drug called EPI-326 in about 110 people with advanced lung cancer (with a specific EGFR gene change) or head/neck cancer. The main goal is to find a safe dose and check for side effects. Researchers will also see if the drug helps shrink tumors.

This study tests whether giving trilaciclib before a chemotherapy drug (sacituzumab tirumotecan) can reduce serious side effects like low white blood cell counts in people with advanced EGFR-mutated non-small cell lung cancer that has stopped responding to standard targeted thera…

This study tests whether using a salt substitute instead of regular salt can help preserve kidney function in people who have had surgery for a kidney tumor. About 200 adults will be randomly assigned to use either a salt substitute or regular salt for one year. Researchers will …

This study is for people with advanced non-small cell lung cancer that has stopped responding to a type of targeted therapy called third-generation EGFR TKIs. Researchers want to see if giving chemotherapy first, followed by a newer targeted drug called befotertinib, can help con…

This study watches 100 adults with metastatic non-small cell lung cancer who have certain EGFR gene changes and are already getting amivantamab plus chemotherapy through an early access program. Researchers want to see how long the cancer stays under control in real-world setting…